Firefly Neuroscience, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 10, 2026, reporting third-quarter revenue of $647 thousand and a net loss of $1,479 thousand.

Key Highlights

  • Revenue increased: Quarterly revenue reached $647 thousand for the three months ended September 30, 2026, compared to $388 thousand for the same period in 2025, according to the filing.
  • Net loss narrowed year-over-year: Net loss for the three months ended September 30, 2026 was $1,479 thousand, compared to $2,639 thousand for the three months ended September 30, 2025.
  • Nine-month net loss: For the nine months ended September 30, 2026, the company reported a net loss of $5,467 thousand, versus $17,402 thousand for the same period in 2025.
  • Cash position improved: Cash and cash equivalents stood at $8,023 thousand as of September 30, 2026, up from $2,747 thousand at December 31, 2025.
  • Total assets grew: Total assets were $15,448 thousand at September 30, 2026, compared to $10,477 thousand at December 31, 2025.
  • Shares outstanding: As of November 6, 2026, there were 15,749,008 shares of common stock outstanding.
  • Basic and diluted loss per share: Loss per share was $0.07 for the three months ended September 30, 2026, and $0.29 for the nine months ended September 30, 2026.

Firefly Neuroscience Reports Q3 2026 Financial Results and Balance Sheet Changes

Firefly Neuroscience, Inc. (NASDAQ:AIFF), a Delaware-incorporated company headquartered at 1100 Military Road, Kenmore, NY 14217, filed its quarterly report covering the period ended September 30, 2026. The filing shows revenue of $647 thousand for the third quarter of 2026, up from $388 thousand in the third quarter of 2025. Cost of goods sold fell to $122 thousand from $242 thousand in the prior-year period, producing a gross profit of $525 thousand versus $146 thousand a year earlier, according to the filing.

Total operating expenses for the three months ended September 30, 2026 were $2,067 thousand, compared to $2,802 thousand in the same quarter of 2025. The operating loss for the quarter was $1,542 thousand, compared to an operating loss of $2,656 thousand a year prior. For the nine months ended September 30, 2026, the company reported an operating loss of $5,526 thousand and a net loss of $5,467 thousand. The prior-year nine-month period included a $9,369 thousand charge related to a change in derivative fair value and a $1,353 thousand loss on settlement, items that did not recur in the current period, as disclosed in the filing.

On the balance sheet, total shareholders' equity increased to $13,428 thousand at September 30, 2026, from $7,637 thousand at December 31, 2025. The equity statement reflects two private placements during the nine-month period: one in Q1 2026 raising net proceeds of $2,236 thousand, and one in Q2 2026 raising net proceeds of $7,892 thousand (including $1 thousand in par value), according to the filing. The accumulated deficit stood at $117,037 thousand at September 30, 2026, compared to $111,615 thousand at December 31, 2025. The company is classified as a non-accelerated filer and smaller reporting company.

What Was Disclosed

Firefly Neuroscience filed its unaudited quarterly report for the period ended September 30, 2026, disclosing revenue of $647 thousand, a net loss of $1,479 thousand for the quarter, cash of $8,023 thousand, and total assets of $15,448 thousand, with 15,749,008 shares outstanding as of November 6, 2026.